Pelvic Organ Prolapse
Conditions
Keywords
incontinence, prolapse, Abdominal sacrocolpopexy
Brief summary
The purpose of this research is to determine if there is a difference in total costs of care and return to health in women who undergo a laparoscopic abdominal sacrocolpopexy (ASC) compared to those undergoing the same procedure with the assistance of a robot. Both traditional laparoscopic and robotic assisted laparoscopic approaches have been found to result in shorter hospital stays, decreased blood loss and similar surgical outcomes as compared to open abdominal surgery. The decision to use robotic assistance is typically based on surgeon preference and robot availability. The study will compare the outcomes of cost, quality of life, and return to work among women who undergo a laparoscopic sacrocolpopexy utilizing the robot to those using traditional laparoscopic techniques. This research study is designed to compare the total costs and treatment success of these two surgical techniques. In addition, the study will compare outcomes of post-operative pain, quality of life, sexual function, return to normal activities and satisfaction with treatment outcome.
Detailed description
Approximately one in ten women undergoes surgery for prolapse or incontinence in her lifetime. Of these, up to thirty percent require a re-operation for recurrence of their prolapse or incontinence symptoms. It has been estimated one in nine women will undergo a hysterectomy in her lifetime, and up to 10% of these women will require surgery for symptomatic vaginal vault prolapse. The search for the ideal repair for pelvic organ prolapse has led to the invention of several approaches to this problem. Abdominal sacrocolpopexy (ASC) with synthetic mesh is considered the gold standard in the surgical management of pelvic organ prolapse with anatomic success rates ranging from 90 to 100%. Randomized comparative effectiveness trials and systematic literature reviews demonstrated the anatomic superiority of open ASC compared to vaginal sacrospinous ligament suspension. Although ASC has the highest anatomic success rates for correcting apical prolapse, it is traditionally done via a laparotomy requiring an abdominal incision. Open technique is associated with more frequent short-term complications, including gastrointestinal. Minimally invasive approaches to ASC using laparoscopy or robotic assisted laparoscopy demonstrate shorter hospital stays, decreased blood loss, and similar short-term anatomic outcomes when compared to open ASC. Increasing numbers of surgeons and patients choose minimally invasive ASC to maximize the benefits of abdominal placed mesh and the shorter-recovery associated with minimally invasive surgery. Few studies have compared laparoscopy to robotic assisted-laparoscopy in pelvic reconstructive surgery. Like many techniques in pelvic surgery, trends in the management of pelvic organ prolapse continue to evolve. Unfortunately, such trends are not supported by robust data, specifically that provided by randomized clinical trials. Although robotic technology is new and rapidly spreading throughout the urologic and gynecologic communities, there are no randomized trials comparing outcomes of robotic to more traditional laparoscopic techniques for reconstructive pelvic surgery. Retrospective series indicate comparable efficacy with respect to cure of prolapse. However, to date is it unknown how robotic surgery compares to laparoscopic techniques with respect to cost, patient safety, pain, and ability to return to normal activities. The use of the robot in laparoscopic surgery is costly. The costs of purchasing a robot has been estimated at $1.5 million dollars with annual maintenance costs of $112,0007. In addition, additional costs exist for the robotic equipment utilized with each case. It is arguable that the maintenance and operative equipment costs may overshadow any potential savings in length of hospital stay and patient convalescence. However, if robotic sacrocolpopexy can provide better immediate quality of life, less pain, and faster recovery compared to laparoscopic techniques, the investment in robotic techniques may very well be cost effective when a societal perspective is taken.
Interventions
Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Stage II to IV pelvic organ prolapse 2. Prolapse of the vaginal apex or cervix to at least half way into the vaginal canal 3. Vaginal bulge symptoms 4. Minimally invasive surgery is planned 5. Available for 12 months of follow-up 6. Able to complete study assessments 7. Able and willing to provide written informed consent
Exclusion criteria
1. Contraindication to laparoscopic or robotically assisted laparoscopic abdominal sacrocolpopexy 2. Subject wishes to retain her uterus (i.e., surgical assignment may involve removal of uterus, if not previously removed)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Cost of Care Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 6 Weeks | At 6-weeks following surgery, the study will measure the total cost of care in dollars and compare this estimate between women assigned to standard vs robotic-assisted laparoscopic abdominal sacrocolpopexy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Urinary Distress Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 6 Months | At 6-months following surgery, the study will measure urinary distress using the Urinary Distress Inventory (UDI) and compare this estimate between women assigned to standard vs robotic-assisted laparoscopic abdominal sacrocolpopexy. The UDI measures urinary incontinence and distress and their effect on daily life. The score range is 0 to 300, with higher scores indicating worsening symptoms. |
Countries
United States
Participant flow
Recruitment details
The recruitment period was from November 2009 to August 2011 (21 months)
Pre-assignment details
Following enrollment, six women withdrew prior to randomization and two women were lost to follow-up prior to randomization
Participants by arm
| Arm | Count |
|---|---|
| Laparoscopic Abdominal Sacrocolpopexy (LASC) Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC) | 38 |
| Robotic Assisted Laparoscopic (RASC) Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC) | 40 |
| Total | 78 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 3 | 2 |
Baseline characteristics
| Characteristic | Robotic Assisted Laparoscopic (RASC) | Laparoscopic Abdominal Sacrocolpopexy (LASC) | Total |
|---|---|---|---|
| Age, Continuous | 58.5 years STANDARD_DEVIATION 10.5 | 60.6 years STANDARD_DEVIATION 9.2 | 59.5 years STANDARD_DEVIATION 9.9 |
| Body Mass Index (BMI) | 28.2 kg/m^2 STANDARD_DEVIATION 6.6 | 27 kg/m^2 STANDARD_DEVIATION 4.7 | 27.7 kg/m^2 STANDARD_DEVIATION 5.7 |
| City and state where the study activities took place Los Angeles, California | 12 Participants | 10 Participants | 22 Participants |
| City and state where the study activities took place Maywood, Illinois | 28 Participants | 28 Participants | 56 Participants |
| Comorbid Diabetes No | 34 Participants | 35 Participants | 69 Participants |
| Comorbid Diabetes Yes | 6 Participants | 3 Participants | 9 Participants |
| Concomitant estrogen therapy No | 34 Participants | 27 Participants | 61 Participants |
| Concomitant estrogen therapy Yes | 6 Participants | 11 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 38 Participants | 36 Participants | 74 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Gender Female | 40 Participants | 38 Participants | 78 Participants |
| Gender Male | 0 Participants | 0 Participants | 0 Participants |
| History of Cancer No | 32 Participants | 32 Participants | 64 Participants |
| History of Cancer Yes | 8 Participants | 6 Participants | 14 Participants |
| History of Heart Attack No | 35 Participants | 37 Participants | 72 Participants |
| History of Heart Attack Yes | 5 Participants | 1 Participants | 6 Participants |
| History of Stomach Ulcer No | 30 Participants | 31 Participants | 61 Participants |
| History of Stomach Ulcer Yes | 10 Participants | 7 Participants | 17 Participants |
| History of Stroke No | 40 Participants | 36 Participants | 76 Participants |
| History of Stroke Yes | 0 Participants | 2 Participants | 2 Participants |
| Net household income $50,000 to $75,000 | 11 Participants | 11 Participants | 22 Participants |
| Net household income Less than $50,000 | 11 Participants | 18 Participants | 29 Participants |
| Net household income More than $75,000 | 15 Participants | 8 Participants | 23 Participants |
| Net household income Unknown | 3 Participants | 1 Participants | 4 Participants |
| Parity | 2.6 Count of pregnancies STANDARD_DEVIATION 1.1 | 2.7 Count of pregnancies STANDARD_DEVIATION 1.3 | 2.7 Count of pregnancies STANDARD_DEVIATION 1.2 |
| Postmenopausal No | 11 Participants | 9 Participants | 20 Participants |
| Postmenopausal Yes | 29 Participants | 29 Participants | 58 Participants |
| Previous surgery for pelvic organ prolapse No | 32 Participants | 30 Participants | 62 Participants |
| Previous surgery for pelvic organ prolapse Yes | 8 Participants | 8 Participants | 16 Participants |
| Previous surgery for urinary incontinence No | 35 Participants | 31 Participants | 66 Participants |
| Previous surgery for urinary incontinence Yes | 5 Participants | 7 Participants | 12 Participants |
| Prior Hysterectomy No | 26 Participants | 19 Participants | 45 Participants |
| Prior Hysterectomy Yes | 14 Participants | 19 Participants | 33 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 36 Participants | 37 Participants | 73 Participants |
| Years of Education 12 or fewer years | 14 Participants | 14 Participants | 28 Participants |
| Years of Education More than 12 years | 26 Participants | 24 Participants | 50 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 8 / 38 | 7 / 40 |
| serious Total, serious adverse events | 0 / 38 | 0 / 40 |
Outcome results
Total Cost of Care Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy
At 6-weeks following surgery, the study will measure the total cost of care in dollars and compare this estimate between women assigned to standard vs robotic-assisted laparoscopic abdominal sacrocolpopexy.
Time frame: 6 Weeks
Population: The analysis for the primary outcome includes all randomized subjects.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Laparoscopic Abdominal Sacrocolpopexy (LASC) | Total Cost of Care Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 11573 Dollars | Standard Deviation 3191 |
| Robotic Assisted Laparoscopic (RASC) | Total Cost of Care Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 19616 Dollars | Standard Deviation 3135 |
Urinary Distress Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy
At 6-months following surgery, the study will measure urinary distress using the Urinary Distress Inventory (UDI) and compare this estimate between women assigned to standard vs robotic-assisted laparoscopic abdominal sacrocolpopexy. The UDI measures urinary incontinence and distress and their effect on daily life. The score range is 0 to 300, with higher scores indicating worsening symptoms.
Time frame: 6 Months
Population: The analysis excludes three individuals assigned to the LASC cohort and two individuals assigned to the RASC cohort because they were lost to follow-up six months after intervention.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Laparoscopic Abdominal Sacrocolpopexy (LASC) | Urinary Distress Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 25.1 units on a scale | Standard Deviation 31.4 |
| Robotic Assisted Laparoscopic (RASC) | Urinary Distress Between Standard and Robotic-assisted Laparoscopic Abdominal Sacrocolpopexy | 31.3 units on a scale | Standard Deviation 35.3 |